300 related articles for article (PubMed ID: 29978271)
1. The efficacy of intracerebroventricular idursulfase-beta enzyme replacement therapy in mucopolysaccharidosis II murine model: heparan sulfate in cerebrospinal fluid as a clinical biomarker of neuropathology.
Sohn YB; Ko AR; Seong MR; Lee S; Kim MR; Cho SY; Kim JS; Sakaguchi M; Nakazawa T; Kosuga M; Seo JH; Okuyama T; Jin DK
J Inherit Metab Dis; 2018 Nov; 41(6):1235-1246. PubMed ID: 29978271
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
Bhalla A; Ravi R; Fang M; Arguello A; Davis SS; Chiu CL; Blumenfeld JR; Nguyen HN; Earr TK; Wang J; Astarita G; Zhu Y; Fiore D; Scearce-Levie K; Diaz D; Cahan H; Troyer MD; Harris JM; Escolar ML
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707880
[TBL] [Abstract][Full Text] [Related]
4. Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice.
Morimoto H; Kida S; Yoden E; Kinoshita M; Tanaka N; Yamamoto R; Koshimura Y; Takagi H; Takahashi K; Hirato T; Minami K; Sonoda H
Mol Ther; 2021 May; 29(5):1853-1861. PubMed ID: 33508431
[TBL] [Abstract][Full Text] [Related]
5. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
Higuchi T; Shimizu H; Fukuda T; Kawagoe S; Matsumoto J; Shimada Y; Kobayashi H; Ida H; Ohashi T; Morimoto H; Hirato T; Nishino K; Eto Y
Mol Genet Metab; 2012 Sep; 107(1-2):122-8. PubMed ID: 22704483
[TBL] [Abstract][Full Text] [Related]
6. Glycosaminoglycan signatures in body fluids of mucopolysaccharidosis type II mouse model under long-term enzyme replacement therapy.
Maccari F; Rigon L; Mantovani V; Galeotti F; Salvalaio M; D'Avanzo F; Zanetti A; Capitani F; Gabrielli O; Tomanin R; Volpi N
J Mol Med (Berl); 2022 Aug; 100(8):1169-1179. PubMed ID: 35816218
[TBL] [Abstract][Full Text] [Related]
7. Intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II: Final report of 5-year results from a Japanese open-label phase 1/2 study.
Seo JH; Kosuga M; Hamazaki T; Shintaku H; Okuyama T
Mol Genet Metab; 2023 Dec; 140(4):107709. PubMed ID: 37922836
[TBL] [Abstract][Full Text] [Related]
8. Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial.
Okuyama T; Eto Y; Sakai N; Minami K; Yamamoto T; Sonoda H; Yamaoka M; Tachibana K; Hirato T; Sato Y
Mol Ther; 2019 Feb; 27(2):456-464. PubMed ID: 30595526
[TBL] [Abstract][Full Text] [Related]
9. High-Throughput Liquid Chromatography-Tandem Mass Spectrometry Quantification of Glycosaminoglycans as Biomarkers of Mucopolysaccharidosis II.
Wang J; Bhalla A; Ullman JC; Fang M; Ravi R; Arguello A; Thomsen E; Tsogtbaatar B; Guo JL; Skuja LL; Dugas JC; Davis SS; Poda SB; Gunasekaran K; Costanzo S; Sweeney ZK; Henry AG; Harris JM; Henne KR; Astarita G
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751752
[TBL] [Abstract][Full Text] [Related]
10. Improvement of CNS defects via continuous intrathecal enzyme replacement by osmotic pump in mucopolysaccharidosis type II mice.
Sohn YB; Lee J; Cho SY; Kim SJ; Ko AR; Nam MH; Jin DK
Am J Med Genet A; 2013 May; 161A(5):1036-43. PubMed ID: 23529876
[TBL] [Abstract][Full Text] [Related]
11. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
Whiteman DA; Kimura A
Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome).
Sohn YB; Cho SY; Park SW; Kim SJ; Ko AR; Kwon EK; Han SJ; Jin DK
Orphanet J Rare Dis; 2013 Mar; 8():42. PubMed ID: 23497636
[TBL] [Abstract][Full Text] [Related]
13. Effect of systemic high dose enzyme replacement therapy on the improvement of CNS defects in a mouse model of mucopolysaccharidosis type II.
Cho SY; Lee J; Ko AR; Kwak MJ; Kim S; Sohn YB; Park SW; Jin DK
Orphanet J Rare Dis; 2015 Oct; 10():141. PubMed ID: 26520066
[TBL] [Abstract][Full Text] [Related]
14. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.
Garcia AR; DaCosta JM; Pan J; Muenzer J; Lamsa JC
Mol Genet Metab; 2007 Jun; 91(2):183-90. PubMed ID: 17459751
[TBL] [Abstract][Full Text] [Related]
15. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Evenstar LB; Kitto KF; Nan Z; Fairbanks CA; Low WC; Kozarsky KF; McIvor RS
Hum Gene Ther; 2017 Aug; 28(8):626-638. PubMed ID: 28478695
[TBL] [Abstract][Full Text] [Related]
16. A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of hunter syndrome.
Chung YK; Sohn YB; Sohn JM; Lee J; Chang MS; Kwun Y; Kim CH; Lee JY; Yook YJ; Ko AR; Jin DK
Glycoconj J; 2014 May; 31(4):309-15. PubMed ID: 24781369
[TBL] [Abstract][Full Text] [Related]
17. Delivery of an Adeno-Associated Virus Vector into Cerebrospinal Fluid Attenuates Central Nervous System Disease in Mucopolysaccharidosis Type II Mice.
Hinderer C; Katz N; Louboutin JP; Bell P; Yu H; Nayal M; Kozarsky K; O'Brien WT; Goode T; Wilson JM
Hum Gene Ther; 2016 Nov; 27(11):906-915. PubMed ID: 27510804
[TBL] [Abstract][Full Text] [Related]
18. Fusion of Rabies Virus Glycoprotein or gh625 to Iduronate-2-Sulfatase for the Treatment of Mucopolysaccharidosis Type II.
Wood SR; Chaudrhy A; Ellison S; Searle R; Burgod C; Tehseen G; Forte G; O'Leary C; Gleitz H; Liao A; Cook J; Holley R; Bigger BW
Hum Gene Ther; 2024 Apr; 35(7-8):232-242. PubMed ID: 37212263
[TBL] [Abstract][Full Text] [Related]
19. Biochemical evaluation of intracerebroventricular rhNAGLU-IGF2 enzyme replacement therapy in neonatal mice with Sanfilippo B syndrome.
Kan SH; Elsharkawi I; Le SQ; Prill H; Mangini L; Cooper JD; Lawrence R; Sands MS; Crawford BE; Dickson PI
Mol Genet Metab; 2021 Jun; 133(2):185-192. PubMed ID: 33839004
[TBL] [Abstract][Full Text] [Related]
20. A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation.
Mashima R; Ohira M; Okuyama T; Onodera M; Takada S
Sci Rep; 2023 May; 13(1):7865. PubMed ID: 37188686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
